Clinical Trial On Dysfunctional Uterine Bleeding DUB Now Conducted by Thomas L. Lyons MD GYN Surgeon



The Center for Women's Care & Reproductive Surgery, headed by laparoscopic pioneer Thomas L. Lyons, MD, is conducting a placebo controlled FDA clinical trial on a drug used to control dysfunctional uterine bleeding (DUB).

The anti-fibrinolytic medication stops the body from breaking down clots in the blood, causing heavy bleeding to diminish. It has been demonstrated in Europe to decrease bleeding after being administered during the acute phase of the cycle.

Some women enrolled in the clinical trial will take the drug sporadically through their cycle, whereas some participants will receive the placebo. It is a randomized double-blind study, meaning neither the physician nor the patient knows who is receiving the drug and who is receiving the placebo, to ensure unbiased clinical results.



Clinical Trial On Dysfunctional Uterine Bleeding DUB Now Conducted by Thomas L. Lyons MD GYN Surgeon